• Product nameAnti-PEG10 antibody
    See all PEG10 primary antibodies
  • Description
    Rabbit polyclonal to PEG10
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide conjugated to KLH, corresponding to a region within N terminal amino acids 1-30 of Human PEG10 (NP_001171891.1, NP_001035242.1, NP_055883.2, NP_001171890.1)

  • Positive control
    • U251 cell line lysates.



Our Abpromise guarantee covers the use of ab112593 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/100 - 1/500. Predicted molecular weight: 80 kDa.


  • FunctionPrevents apoptosis in hepatocellular carcinoma (HCC) cells through interaction with SIAH1, a mediator of apoptosis. May also have a role in cell growth promotion and hepatoma formation. Inhibits the TGF-beta signaling by interacting with the TGF-beta receptor ALK1. When overexpressed, induces the formation of cellular extension, such as filipodia in association with ALK1. Involved at the immediate early stage of adipocyte differentiation (By similarity). May bind to the 5'-GCCTGTCTTT-3' DNA sequence of the MB1 domain in the myelin basic protein (MBP) promoter.
  • Tissue specificityExpressed in the cytotrophoblast layer but not in the overlying syncytiotrophoblast of the placenta. Expressed in prostate and breast carcinomas but not in normal breast and prostate epithelial cells. Expressed in the HepG2 cell line (at protein level). Expressed in brain, liver, spleen, kidney, thymus, lung, ovary, testis, reactive lymph node, skeletal muscle, adipose tissue and placenta. Expressed in pancreatic and hepatocellular carcinomas (HCC).
  • Sequence similaritiesContains 1 CCHC-type zinc finger.
  • Developmental stageExpressed in placenta during the first trimester of gestation (at protein level). In placenta, down-regulated at early hypoxic phase, and highly activated at 11-12 week of gestation.
  • Post-translational
    Isoform RF1/RF2 undergoes proteolytic cleavage.
  • Cellular localizationNucleus. Cytoplasm. Detected predominantly in the cytoplasm of breast and prostate carcinomas, in hepatocellular carcinoma (HCC) and B-cell chronic lymphocytic leukemia (B-CLL) cells and in the HepG2 cell line. Colocalized with ALK1.
  • Information by UniProt
  • Database links
  • Alternative names
    • AA407948 antibody
    • Edr antibody
    • Embryonal carcinoma differentiation regulated antibody
    • Embryonal carcinoma differentiation-regulated protein antibody
    • HB 1 antibody
    • HB1 antibody
    • KIAA1051 antibody
    • Mammalian retrotransposon-derived protein 2 antibody
    • Mar2 antibody
    • Mart2 antibody
    • MEF3 like 1 antibody
    • MEF3-like protein 1 antibody
    • MEF3L antibody
    • MEF3L1 antibody
    • MyEF 3 antibody
    • Myelin expression factor 3-like protein 1 antibody
    • Paternally expressed 10 antibody
    • Paternally expressed gene 10 ORF1 antibody
    • Paternally expressed gene 10 protein antibody
    • Peg10 antibody
    • PEG10 protein antibody
    • PEG10_HUMAN antibody
    • Putative uncharacterized protein PEG10 antibody
    • Retrotransposon gag domain containing 3 antibody
    • Retrotransposon gag domain-containing protein 3 antibody
    • Retrotransposon-derived gag-like polyprotein antibody
    • Retrotransposon-derived protein PEG10 antibody
    • RGAG3 antibody
    • Ty3/Gypsy-like protein antibody
    see all

Anti-PEG10 antibody images

  • Anti-PEG10 antibody (ab112593) at 1/100 dilution + U251 cell line lysates at 35 µg

    Predicted band size : 80 kDa

References for Anti-PEG10 antibody (ab112593)

ab112593 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab112593.
Please use the links above to contact us or submit feedback about this product.